20.65
+0(+0.00%)
Currency In USD
Address
233 Wilshirre Boulevard
Santa Monica, CA 90401
United States of America
Phone
310 598 5410
Website
Sector
Healthcare
Industry
Biotechnology
Employees
37
First IPO Date
June 04, 2007
| Name | Title | Pay | Year Born |
| Dr. Roger Crystal M.D. | Pres, Chief Executive Officer & Director | 1.01M | 1976 |
| Mr. David D. O'Toole | Chief Financial Officer | 624,739 | 1959 |
| Dr. Phillip Skolnick D.Sc. (hon), Ph.D. | Chief Scientific Officer | 638,175 | 1947 |
| Dr. Mark Heath Ellison Ph.D. | Chief Devel. Officer | 0 | N/A |
| Mr. Matthew R. Ruth | Chief Commercial Officer | 0 | 1970 |
| Mr. Ben Atkins | Vice President of Communications & Investor Relations | 0 | N/A |
| Mr. Brian Gorman | EVice President Corporation Devel. & Gen. Counsel | 0 | N/A |
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.